Zheng Bingyi, Wang Xueting, Guo Meizhai, Tzeng Chi-Meng
Cells Good (Xiamen) Inc. Huli, Xiamen Torch Development Zone, Fujian, China.
Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Cell Transplant. 2025 Jan-Dec;34:9636897241297623. doi: 10.1177/09636897241297623.
Mesenchymal stem cells (MSCs) are pluripotent stem cells with self-renewal. They play a critical role in cell therapy due to their powerful immunomodulatory and regenerative effects. Recent studies suggest that one of the key therapeutic mechanisms of MSCs seems to derive from their paracrine product, called extracellular vesicles (EVs). The EVs contain much DNA, messenger RNA (mRNA), microRNA, and protein components, which can exert intracellular communication to target cells. In clinical applications, the MSC-EVs have been widely used in tissue repair and immune disorder diseases. However, there are serval issues need to be considered such as how to accomplish the large-scale production of EVs and how to verify the exact mechanism of EVs. In this review, we summarize the current progress of MSC-EVs and discuss the challenges and future of MSC-EVs.
间充质干细胞(MSCs)是具有自我更新能力的多能干细胞。由于其强大的免疫调节和再生作用,它们在细胞治疗中发挥着关键作用。最近的研究表明,MSCs的关键治疗机制之一似乎源于其分泌的一种称为细胞外囊泡(EVs)的旁分泌产物。EVs包含大量的DNA、信使核糖核酸(mRNA)、微小核糖核酸和蛋白质成分,这些成分可以与靶细胞进行细胞内通讯。在临床应用中,MSC-EVs已广泛用于组织修复和免疫紊乱疾病。然而,仍有几个问题需要考虑,例如如何实现EVs的大规模生产以及如何验证EVs的确切作用机制。在这篇综述中,我们总结了MSC-EVs的当前进展,并讨论了MSC-EVs面临的挑战和未来发展方向。